Conditions: Essential Hypertension
Keywords: Essential hypertension LCZ696
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1161
Healthy volunteers: no

Brief summary:
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension

Detailed description:

Arms:
arm 1: LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks arm 2: LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks arm 3: Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks

Interventions: intervention 1: LCZ696 intervention 2: Olmesartan intervention 3: Placebo
Intervention descriptions: intervention 1: 200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily intervention 2: Olmesartan 20 mg capsule one daily intervention 3: Placebo to LCZ696 or Olmesartan

Protocol document: